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Alzheimer’s disease is the most common cause of dementia, 
affecting around 50 million people worldwide. Its preva-
lence is increasing mainly as a result of an ageing population 
with considerable associated increases in health and social 
care costs. As a result, government agencies worldwide 
have turned funding streams towards unravelling biologi-
cal mechanisms and developing therapeutic opportunities 
for the dementias in general. Consequently, a number of 
novel potential treatments have been developed, although, 
to date, they have not been shown to significantly alter dis-
ease course. In this month’s journal club we look at three 
large clinical trials of new treatments in Alzheimer’s disease.
Trial of solanezumab for mild dementia due 
to Alzheimer’s disease
This paper describes a randomised, controlled, double-blind, 
multi-centre trial of a monoclonal antibody, solanezumab, in 
mild Alzheimer’s disease (EXPEDITION 3). Solanezumab 
is a humanised monoclonal antibody that binds to amyloid 
beta (Aβ) and increases its clearance. Participants were 
eligible if they were between 55 and 90 years of age, had 
probable mild Alzheimer’s disease (mini mental state exam 
score of between 20 and 26), and had PET or CSF evidence 
of cerebral beta-amyloid deposition. The primary outcome 
measure was change in the ADAS-cog14 (Alzheimer’s Dis-
ease Assessment Scale 14-item cognitive subscale) score at 
80 weeks.
2129 patients were randomised, with 1057 patients 
receiving 400 mg of solanezumab and 1072 having monthly 
placebo infusions. There was no significant difference 
between the treatment and control groups in terms of pri-
mary outcome measure. ADAS-cog14 scores changed by 
6.65 in the solanezumab group and 7.44 in the placebo 
group, difference, − 0.80; P = 0.10 (higher scores in ADAS-
cog14 indicating worsening performance). The trial had a 
pre-specified hierarchical analysis and so, given the lack of 
a significant difference between groups in the primary out-
come, significance testing was not performed on secondary 
outcomes. As with other human and animal studies of solan-
ezumab there was a significant reduction in soluble free Aβ 
concentration (90%) in the treatment arm.
There were no significant differences between the groups 
in terms of adverse effects and amyloid-related abnormali-
ties on imaging (a concern which had arisen following 
observations in trials of other monoclonal antibodies that 
directly target amyloid plaques).
Comment. This was a large and well-conducted trial 
which did not show a significant difference with treatment 
with an amyloid beta monoclonal antibody. This is now the 
third randomised control trial of solanezumab and previous 
trials (EXPEDITION 1 and 2) also did not reach significance 
in primary endpoints although did show some effect in slow-
ing cognitive decline in secondary analysis. Solanezumab 
does reduce free Aβ concentrations but this does not seem 
to translate into clinical benefit.
Honig et al. (2018) N Engl J Med 378:321–330.
24‑month intervention with a specific 
multinutrient in people with prodromal 
Alzheimer’s disease (LipiDiDiet): 
a randomised, double‑blind, controlled trial
This paper describes a randomised, controlled, double-blind 
trial of a dietary supplement (Fortasyn Connect) in prodro-
mal Alzheimer’s disease (LipiDiDiet). Participants were 
recruited from memory clinics and were eligible if they 
were between 55 and 85 years old, had a Mini-Mental State 
Examination (MMSE) of at least 24 (20 if lower levels of 
education), and fulfilled criteria for prodromal Alzheimer’s 
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disease including evidence of Alzheimer’s disease pathol-
ogy in CSF, MRI or PET analysis. Participants were ran-
domised to a drink containing Fortasyn Connect (a combina-
tion of docosahexaenoic and eicosapentaenoic acid, uridine 
monophosphate, choline, vitamins, phospholipids, and sele-
nium) or a placebo. This specific combination is designed to 
provide neuroprotection by providing compounds for brain 
phospholipid synthesis and addressing multiple Alzheimer’s 
disease-related processes. The primary outcome was the 
change in a composite score of a neuropsychological test 
battery over the 2 years of the trial period. The neuropsy-
chological test battery included tests of immediate recall, 
delayed recall, word recognition and category fluency.
311 patients were randomised (mean age 71, 50% male) 
with 153 in the treatment group and 158 in the placebo 
group. 59 (37%) participants in the control group and 62 
(41%) participants in the treatment group were diagnosed 
with dementia during the trial. There was no significant dif-
ference between the groups in the primary end point. There 
were no significant differences in four of the secondary 
end points (changes in MRI whole brain volume, memory 
domain, executive function domain and total neuropsycho-
logical battery score). The treatment did show benefit in 
three of the secondary outcomes: there was a slower hip-
pocampal atrophy rate, a smaller increase in ventricular vol-
ume and less worsening in the clinical dementia rating-sum 
of boxes scores in the treatment group.
Comment. This was a well-conducted trial and the first 
published trial of a non-pharmacological intervention in pro-
dromal Alzheimer’s disease. A dietary supplement seems 
an attractive option as a treatment for Alzheimer’s disease 
compared with powerful pharmacological agents, but this 
trial does not provide enough evidence for use of Fortasyn 
Connect in prodromal Alzheimer’s disease.
Soininen et al. (2017) Lancet Neurol. 16:965–75.
Randomized trial of verubecestat 
for mild‑to‑moderate Alzheimer’s disease
This paper describes a randomised, double-blind, multi-cen-
tre trial of verubecestat in mild and moderate Alzheimer’s 
disease. Verubecestat inhibits β-site APP–cleaving enzyme 
1 (BACE-1; ) and therefore prevents the cleavage of amyloid 
precursor protein to Aβ. Participants were eligible if they 
were between 55 and 85 years old, had probable Alzhei-
mer’s disease, and a mini mental state examination score of 
between 15 and 26. The primary outcomes were changes in 
scores in the cognitive sub-scale of the Alzheimer’s disease 
Assessment Scale (ADAS-cog) and Alzheimer’s Disease 
Cooperative Study Activities of Daily Living Inventory scale 
(ADCS-ADL) (a measure of day to day function).
1958 patients were randomised; 653 received 12 mg of 
verubecestat daily, 652 received 40 mg of verubecestat daily 
and 653 received placebo. The trial was terminated 5 months 
prematurely due to futility—there were no significant differ-
ences between the verubecestat groups and placebo in terms of 
primary outcomes. The verubecestat groups did have a signifi-
cant reduction in CSF A − 40, A − 42 and sAPPβ levels when 
compared with the placebo group. There were more adverse 
events in the treatment groups. Specific adverse events which 
were more common in the treatment group included falls, rash, 
weight decrease, hair colour change and suicidal ideation.
Comment. Another large and well-constructed trial which 
did not reach significance in its primary outcomes. It seems 
that the drug is effective in reducing CSF levels of Aβ but 
this does not translate into clinical benefit. There seemed to 
be more adverse effects with this drug when compared with 
other treatments.
Egan et al. (2018) N Engl J Med. 378:1691–703.
Conclusion
The three papers we have reviewed in this journal club rep-
resent large, well-constructed, randomised controlled trials 
in new and promising treatments for Alzheimer’s disease. 
Despite all three treatments having significant pre-clinical 
and clinical evidence for their suitability in treating Alzhei-
mer’s disease, all three failed to reach their primary outcomes. 
Although disappointing for the researchers and patients with 
Alzheimer’s disease, it is important that lessons can be learnt 
from these ‘negative’ results, in particular in the evolution of 
trial design in this discipline, and it is refreshing for the meth-
odology and evidence to be presented in high-impact journals.
There are several potential reasons for the failure of these 
treatments to show significant clinical effects, the most 
important being perhaps that participants are too far into 
their disease course to benefit from these treatments by the 
time they have started the trials. This might mean that target-
ing preventative treatments at a population level is a more 
sensible approach. However, efforts to develop a disease-
modifying treatment remains a priority for healthcare pro-
viders worldwide, as effective intervention would have the 
potential to transform the lives of millions of people with 
Alzheimer’s disease and their carers who are affected by the 
debilitating consequences of this disease.
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